key: cord-0964828-hhz8u79n
authors: Klegerman, M. E.; Peng, T.; Seferovich, I.; Rahbar, M. H.; Hessabi, M.; Tahanan, A.; Wanger, A.; Grimes, C. Z.; Ostrosky-Zeichner, L. Z.; Koster, K.; Cirillo, J. D.; Abeydeera, D.; De Lira, S.; McPherson, D. D.
title: Protective characteristics of COVID-19 convalescent and post-vaccination IgG antibodies
date: 2021-11-21
journal: nan
DOI: 10.1101/2021.11.19.21266547
sha: cad4aee7934e7f3a563f8992fc583ae1f7668b0e
doc_id: 964828
cord_uid: hhz8u79n

Soon after commencement of the SARS-CoV-2 disease outbreak of 2019 (COVID-19), it became evident that the receptor-binding domain of the viral spike protein is the target of neutralizing antibodies that comprise a critical element of protective immunity to the virus. This study addresses the relative lack of information regarding actual antibody concentrations in convalescent plasma samples from COVID-19 patients and extends these analyses to post-vaccination samples to estimate protective IgG antibody (Ab) levels. Both sample populations were similar and a protective Ab level of 7.5 g/ml was determined, based on 95% of the normal distribution of the post-vaccination population. The results of this study have implications for future vaccine development, projection of protective efficacy duration, and understanding of the immune response to SARS-CoV-2 infection.

The coronavirus disease outbreak of 2019 , caused by a newly emerging coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected 253 million people worldwide, resulting in more than 5.1 million deaths (756,000 in the U.S.), nearly two years after initial cases appeared in Wuhan, China, in December 2019 (1) . The outstanding structural feature of coronaviruses (from which they derive their crown-like designation) is the protruding spikes that mediate attachment of the spherical virions to host cells and subsequent fusion with epithelial cell membranes, required for entry and infection. The spike glycoprotein (SP) that forms these structures is a homotrimer consisting of two subunits, S1 and S2. The S1

protein binds to the angiotensin converting enzyme-2 (ACE-2) receptor on the cell surface through the receptor-binding domain (RBD), while the S2 protein mediates cell membrane fusion (2) .

It is readily hypothesized, therefore, that the RBD is the target of neutralizing antibodies that comprise the critical element of protective immunity to the virus. This hypothesis is supported by the finding that the RBD is immunodominant and the target of 90% of the neutralizing activity present in SARS-CoV-2 immune sera (3) . Most compelling is the established 95% protective efficacy of the two mRNA COVID-19 vaccines developed by Pfizer and Moderna, which elicit antibodies specific for the RBD (4) . Although many studies have focused on characterization of the antibody response to SARS-CoV-2, emphasis has largely been on antibody properties that are most relevant to effective vaccine development, such as the ability of patients to produce high-affinity IgG antibodies specific for the RBD (2, (5) (6) (7) (8) , or production of therapeutic monoclonal antibody formulations (3, (9) (10) (11) . Studies of actual antibody concentrations, binding affinities in terms of equilibrium constants, and non-RBD epitope targeting in convalescent plasma (CP) samples have been largely lacking, however.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org /10.1101 /10. /2021 We report here the determination of eight different parameters addressing these variables in 21 convalescent plasma samples, using quantitative ELISA methodology (Table 1) . We then applied these methods to characterization of 21 plasma samples obtained from individuals who completed the two mRNA vaccination protocols (post-vaccination, PV). Knowing the protective efficacy of these vaccines, which were virtually identical, we were able to estimate protective IgG anti-SP antibody levels and analogous values for two indexes that combined antibody concentrations and binding affinities for both the SP and the RBD.

First, we examined Pearson correlations between each pair of four parameters of interest.

The results did not reveal any significant correlations between each pair of parameters. The details are shown in Table 2 . The overall comparison of means between CP and PV groups for all parameters based on Multivariate analysis of variance (MANOVA) revealed statistically significant differences for at least one of the parameters, (P < 0.002). Further comparisons between the two groups for each parameter by the two-sample t-test also confirmed significant differences between the two groups for SP Affinity, SP/SP (KD), and Specific Index between CP and PV groups. The results from both statistical methods are displayed in Table 3 .

Furthermore, although there was no statistically significant difference between mean IgG antibody concentrations between CP and PV in unadjusted Generalized Linear Model (GLM) (p = 0.35), when adjusted for SP Affinity (KD), there was a significant difference (P = 0.001) between the two groups. Additional results are displayed in Table 4 .

In the recombinant spike protein (rSP) ELISA, the superimposability of normal human plasma spiked with human anti-SP IgG standard (GenScript, Piscataway, NJ), a measure of assay accuracy, is shown in Supplementary Figure 2 (Figure S2 ). Four normal human plasma samples exhibited antibody concentrations of 28.8 ± 13.0 (SE) ng/ml in the assay, which defines the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.19.21266547 doi: medRxiv preprint lower limit of specific COVID-19 antibody response, and recoveries of standard from the pooled normal plasma ranged from 94.5% to 132.5% (mean = 109.7%) from 6.25-100 ng Ab/ml. Antibody standard binding affinity for the spike protein, with correction for post-antibody ELISA incubations (12) , was found to be 1.46 ± 0.48 nM (KD)(SD, n = 29). Binding affinity of ACE-2 Fc for the spike protein was found to be 2.20 ± 0.60 nM (n = 6), which is similar to published values (2) . Dilutions of both convalescent and post-vaccination plasma samples were superimposable on the respective standard curves ( Figures 1A and 1B) , indicating that the chimera antibody protein standards are suitable for quantitating anti-SP IgG antibodies in human plasma and serum samples.

Anti-SP IgG antibody levels for the convalescent plasma population (n = 21) ranged from 33.1 µg/ml to 1.6 mg/ml, while the corresponding values for the post-vaccination plasma population (n = 21) ranged from 4.9 µg/ml to 1.5 mg/ml (Fig. 1C) . The geometric means of the two populations were 190 and 176 µg/ml, respectively. The protective antibody plasma concentration, determined as the 5 th percentile level of the post-vaccination distribution, is 7.5 µg/ml. SP binding affinities (KD) of convalescent plasma samples ranged from 0.1 to 2.2 nM (mean = 0.87 ± 0.47 nM), while the range of RBD binding affinities was much narrower, all being subnanomolar (mean = 0.49 ± 0.15 nM). Spike protein binding affinities of postvaccination plasma IgG antibodies were lower (p = 0.0001) and somewhat broader (0.2-3.9; 1.95 ± 0.99 nM than those of the convalescent antibody populations. However, the post-vaccination anti-RBD affinities were virtually the same (0.48 ± 0.34 nM; p = 0.877), as were the EC50 values, the molar antibody concentration required to produce 50 percent inhibition of a set concentration of ACE-2 binding to the RBD, a putative measure of neutralizing capacity ( Figure 1D ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 1 .

Based on the criteria of log ranges greater than two and low values in the postvaccination population below the putative protective level, the most useful indexes appear to be the antibody levels themselves, and the two RBD indexes. This may reflect the narrow range of RBD binding affinities, all of which were higher than that of the ACE-2 protein. Comparison of antibody characteristics between the two populations indicates that natural infection with SARS-CoV-2 confers protective levels of humoral immunity on the survivors. Measures of both the quantity and affinity (binding strength) of IgG antibodies for the whole spike protein were . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint greater in the convalescent patient population, possibly reflecting that the mRNA vaccines produce antibodies more specific for the RBD. None of the parameters significantly correlated with the EC50 values. The best correlation for the convalescent plasma samples was found for the specific index ( Figure S3A ), combining anti-SP Ab concentration, SP affinity and RBD cross-reactivity (r = 0.328, p = 0.171).

The best correlation for the post-vaccination samples was found for the RBD affinity (r = 0.362, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.19.21266547 doi: medRxiv preprint p = 0.107) ( Figure S3B ). The Carterra LSA RBD ELISA technology yielded titers for 20 convalescent plasma samples ranging from 20.7 to 1,326 (Geom. Mean = 121). A significant linear correlation was found between the LSA RBD titers and the SP IgG antibody levels (r = 0.464, p = 0.039) ( Figure S4 ), validating the approach by two different methods. Another approach to validation of the anti-SP IgG concentrations is comparison with previously published studies, all of which expressed antibody levels as some form of titer.

Relevant data from 9 studies, including the anti-RBD IgG LSA titers reported in this study, are summarized in Table 5 . All but one of these studies were characterized by log titer ranges of 1.81 to 4.70. One very recent study of post-vaccination samples, involving immunoassaydetermined levels of anti-SP and anti-RBD IgG and neutralization titers against both pseudovirus and live SARS-CoV-2 virus (13), exhibited log ranges for all parameters very close to those found for anti-SP IgG in this study.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Factors for conversion of titers to antibody concentrations (µg/ml), based on equivalence of geometric means are included in Table 5 . Neutralization titers show the greatest equivalence, with all but one ranging from 0.85 to 1.96. The anti-RBD IgG LSA titers tended to be lower than the corresponding anti-SP IgG levels, which is reflected in a regression slope of 0.300 ( Figure S4 ), and is consistent with the expectation that anti-RBD levels will be lower than anti-SP levels.

In a recent meta-analysis of neutralization data from seven vaccine studies, Khoury et al. (14) calculated that 50 percent protection against detectable SARS-CoV-1 infection would be afforded by 20.2% of the geometric mean convalescent level of neutralizing antibody. That level for this study is 2.9 μg IgG anti-SP/ml, which is consistent with the 7.5 µg/ml value for 95%

protection. Using the conversion factors tabulated in Table 2 , the 50% protective values of titers calculated by the Oxford Vaccine Group (13) correspond to a minimum of 9.7µg/ml for anti-RBD IgG.

In order to provide a means of standardizing the many COVID-19 antibody assays that have been utilized, the UK National Institute for Biological Standards and Control (NIBSC) has made available panels of pooled convalescent plasma defined by the WHO International . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.19.21266547 doi: medRxiv preprint Standard in IU/ml (15) . This standard was utilized in assessing quantitative differences between Moderna (mRNA-1273) vaccine recipients who had COVID-19 breakout infections (n = 36) and those who did not (n = 1,005) (16) . The geometric mean anti-SP IgG level for infected individuals 28 days after the second vaccine dose was 1,890 IU/ml, while the GM for uninfected individuals was 2,652 IU/ml. The corresponding values for anti-RBD IgG were 2,744 and 3,937 IU/ml, respectively. In view of the results of this study, a much larger difference between the two populations would be expected.

All of these reports emphasized the importance to further vaccine development and refinement of knowing the protective antibody levels in the peripheral circulation. It will also be important to monitoring the decay of protective immunity after vaccination and relating it to the occurrence of breakout infections. It should be emphasized that measuring antibody binding affinity adds value to assessing the robustness of the antibody response, leading to the conclusion in this study that naturally acquired immunity after SARS-CoV-2 infection is comparable to vaccine-induced immunity. It remains to be determined how the former compares to the latter in terms of persistence. These measures will also enable a realistic assessment of immune evasion by viral variants. anti-RBD IgG in fully vaccinated individuals ( Table 1) , 99% of SP molecules would be bound by antibody. This calculation provides a conceptual framework that is consistent with the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.19.21266547 doi: medRxiv preprint empirical data reported here and the foundation for development of a true protective index based on examination of plasma.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Authors declare that they have no competing interests.

Small quantities of plasma samples are available to researchers for purposes of reproducing or extending the analysis, subject to materials transfer agreements. Raw data not included in the supplementary materials are available by individual arrangement.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Materials and Methods Figs. S1 to S4 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

This is a direct ELISA in which the antigen is adsorbed directly onto microtiter wells, as we previously described for fibrinogen (12) . Incubation volumes were 50 µl and all incubations except for the initial coating step were at 37 o C. After the blocking step, all incubations were followed by three washes with 0.02 M phosphate-buffered saline, pH 7.4 with 0.05% Tween-20 (PBS-T). Test wells were coated with 5 µg recombinant spike protein (rSP; S1+S2; Creative is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.19.21266547 doi: medRxiv preprint was solved for x. Binding affinities with correction for conjugate incubation perturbation were determined as previously described (11) . A correction nomogram for this ELISA is reproduced in Figure S1A .

This is a sandwich ELISA in which a capture antibody, rabbit anti-mouse IgG, is adsorbed onto microtititer wells, followed by antigen capture. Test wells were coated with 2,000X diluted rabbit anti-mouse IgG (Sigma-Aldrich) in coating buffer overnight at 4 o C. After blocking, 0.5 µg RSD-mFc (GenScript)/ml PBS-T was added to all wells and incubated for 2 hours. Human anti-SP IgG standards (in serial dilutions of 100-6.25 ng/ml PBS-T) and convalescent plasma samples (3 dilutions within the measurable range, previously determined in a screening assay) were incubated in duplicate for 1 hour. The rest of the ELISA protocol was the same as the rSP ELISA. The ODs of PBS-T only wells run in each assay were subtracted from test well ODs. Calculations of standards and sample antibody concentrations were performed as for the rSP ELISA. A correction nomogram for this ELISA is reproduced in Figure   S1B .

In the spike protein ELISA, binding of ACE-2 to the SP was determined by incubating binding was compared between regions that had either serum antibodies bound to RBD or no serum antibodies bound.

As part of descriptive analyses, we examined the distributions of the IgG antibody characteristics (e.g., SP Affinity) for subjects in each of the two groups. If the distribution of an . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.19.21266547 doi: medRxiv preprint IgG antibody characteristic was skewed, we performed log transformation to produce distributions that better represented a normal distribution for subjects in each of the two groups, convalescent plasma (CP) and post-vaccination (PV). We evaluated the linear associations between each pair of IgG antibody parameters using Pearson correlation coefficients or its nonparametric counterpart measure to examine a linearity. In order to control for probability of type I error, first we used multivariate analysis of variance (MANOVA) to compare all means between IgG antibody characteristics. If a significant difference was found, we used t-tests to identify characteristics for which the means between the two groups were statistically different.

We used the Generalized Linear Model (GLM) for assessing potential confounding factors or interactions between the study groups and each of the factors associated with IgG antibody concentrations.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.19.21266547 doi: medRxiv preprint

World Health Organization Coronavirus (COVID-19) Dashboard

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology

Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Lipid contribution to the affinity of antigen association with specific antibodies conjugated to liposomes

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

WHO International Standard for anti-SARS-CoV-2 immunoglobulin

COVID-19 vaccine efficacy trial

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

Regulation of the depth and composition of airway surface liquid

Rapid generation of neutralizing antibody responses in COVID-19 patients

Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection

Antibody responses to SARS-CoV-2 in patients with COVID-19

COVID-19-neutralizing antibodies predict disease severity and survival

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection